We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Illumina Receives FDA 510(k) Clearance for its BeadXpress® Multiplex Analysis System
News

Illumina Receives FDA 510(k) Clearance for its BeadXpress® Multiplex Analysis System

Illumina Receives FDA 510(k) Clearance for its BeadXpress® Multiplex Analysis System
News

Illumina Receives FDA 510(k) Clearance for its BeadXpress® Multiplex Analysis System

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Illumina Receives FDA 510(k) Clearance for its BeadXpress® Multiplex Analysis System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Illumina, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for the company's BeadXpress system for multiplex genetic analysis.

According to the FDA's indications of use, the BeadXpress system - consisting of Illumina's BeadXpress Reader and VeraScan software - is an in-vitro diagnostic device intended for the simultaneous detection of multiple analytes in a DNA sample utilizing VeraCode holographic microbead technology.

"This approval represents a significant and exciting transitional step for Illumina into the diagnostics field, where the potential is great for molecular medicine to make a real difference in the way disease is detected and ultimately prevented and treated," said Jay Flatley, president and CEO.

He continues, "It demonstrates Illumina's ability to meet stringent regulatory requirements in designing and manufacturing an FDA-cleared in-vitro diagnostic device. This will serve as an important foundation for our future plans in the diagnostics area. Ultimately, our goal is to become a leader in translational medicine, focusing on complex diseases that benefit from high performance analysis, including genotyping, copy number, gene expression, methylation and protein analysis."

Illumina introduced the BeadXpress system in 2007 with Research Use Only kits for custom genotyping, gene expression, methylation and protein analysis. Since then it has been adopted by research, agricultural, industrial and pharmaceutical institutions worldwide.
Advertisement